Glenmark Pharmaceuticals has released its unaudited financial results for Q2 and the half-year ending September 30, 2025. The Board has also approved reconstitution of the Environment, Social and Governance (ESG) Committee, appointing Mr. Pradeep Kumar Sinha as Chairman, effective December 1, 2025. The company is addressing legal challenges with a provision of Rs. 3,232.32 million for settlement, noted as an exceptional item.
Financial Performance Overview
Glenmark Pharmaceuticals has announced its unaudited financial results for the second quarter (Q2) and half-year, which concluded on September 30, 2025. These results, reviewed by the Audit Committee and approved by the Board on November 14, 2025, reflect the company’s performance during this period. The earnings are subject to a limited review by statutory auditors.
Key Financial Figures (Standalone)
- Revenue from operations: Rs 15,386.60 million for Q2 and Rs 39,335.88 million for the half-year.
- Total Income: Rs 18,244.16 million for Q2 and Rs 42,886.79 million for the half-year.
- Profit/(loss) after tax: (Rs 7,391.89 million) for Q2 and (Rs 4,089.63 million) for the half-year.
Key Financial Figures (Consolidated)
- Revenue from operations: Rs 60,468.70 million for Q2 and Rs 93,113.10 million for the half-year.
- Total Income: Rs 62,474.99 million for Q2 and Rs 95,383.81 million for the half-year.
- Profit/(loss) after tax: Rs 6,104.32 million for Q2 and Rs 6,574.05 million for the half-year.
Committee Reconstitution
The Board has approved the reconstitution of the Environment, Social and Governance (ESG) Committee, effective December 1, 2025. Mr. Pradeep Kumar Sinha has been appointed as the Chairman, with Mr. Glenn Saldanha, Ms. Sona Saira Ramasastry, and Ms. Patricia Andrews serving as members.
Exceptional Items and Legal Matters
The company is addressing legal challenges, primarily involving antitrust and consumer protection lawsuits in the U.S. A provision of Rs. 3,232.32 million (US$ 37.75 million) has been made for a settlement related to direct purchaser class actions, recorded as an exceptional item for the quarter ended June 30, 2025. Additional settlements with other plaintiffs, including United Healthcare Services, have also impacted the financial results. A settlement amount of Rs. 598.15 with Humana, Centene, and Kaiser was recorded in March 2025.
Other Key Highlights
- The Board approved an interim dividend of Rs. 2.50 per equity share.
- IGI TSA, a subsidiary of Glenmark, entered an exclusive licensing agreement with AbbVie for ISB 2001, receiving an upfront payment of USD 700 million.
Source: BSE
